FAQContact usTerms of servicePrivacy Policy

FDA approves comprehensive gastroenteritis test

Friday January 18, 2013
Printer Icon
line
Select Text Size: Zoom In Zoom Out
line
Comment
Share this Nurse.com Article
rss feed
The U.S. Food and Drug Administration has allowed marketing of the first test that can simultaneously detect 11 common viral, bacterial and parasitic causes of infectious gastroenteritis from a single patient sample.

Common symptoms of infectious gastroenteritis include vomiting and diarrhea, which can be more severe in infants, the elderly and people with suppressed immune systems. Gastroenteritis can be spread easily through person-to-person contact and contaminated food, water and surfaces.

The Centers for Disease Control and Prevention reports that between 1999 and 2007, gastroenteritis-associated deaths in the United States increased from nearly 7,000 to more than 17,000 per year. Norovirus and Clostridium difficile accounted for two-thirds of the deaths.

The xTAG Gastrointestinal Pathogen Panel, a multiplexed nucleic acid test, detects the following causes of gastroenteritis:

Bacterium — Camplyobacter, C. difficle toxin A/B, Escherichia coli O157, Enterotoxigenic E. coli LT/ST, Salmonella, Shigella, Shiga-like Toxin producing E. coli stx 1/stx 2;

Virus — Norovirus, Rotavirus A;

Parasite — Cryptosporidium, Giardia.

"Tests such as the XTag GPP that can detect viruses, bacteria and parasites from one sample at the same time can help clinicians more quickly identify and treat what’s causing gastroenteritis," Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics and Radiology at the FDA’s Center for Devices and Radiological Health, said in a news release. "The test could also allow clinicians and public health professionals to more quickly identify and investigate the source of potential gastroenteritis outbreaks."

The FDA reviewed data for the xTag GPP through the de novo classification process, a regulatory pathway for medical devices that are generally low- to moderate-risk and are not comparable to an already legally marketed device.

The manufacturer demonstrated the performance of the xTAG GPP by collecting samples from 1,407 patients with suspected infectious gastroenteritis and comparing the xTAG GPP results to individual tests that are known to separately and reliably detect the 11 viruses, bacteria or parasites associated with the xTAG GPP. The manufacturer also ran the test on 203 samples from patients with previously confirmed infectious gastroenteritis and 313 additional specimens from pediatric patients with suspected infectious gastroenteritis. Results were comparable to the individual tests.

Due to the risk of false positives, all positive results from the xTAG GPP need to be confirmed by additional testing, the FDA stated. Luminex Inc., of Austin, Texas, manufactures the xTAG.


Send comments to editor@nurse.com or post comments below.